Cystic Fibrosis Triplet Could Unblock EU Reimbursement Impasse
Cystic fibrosis specialist Vertex remains at loggerheads with HTAs in England and France over its product pricing, but hopes its triplet regimes can eventually break the impasse.
You may also be interested in...
Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.